First-in-human study of FLX925, an orally administered FLT3/CDK4/CDK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML).
- Resource Type
- Journal
- Source
JOURNAL OF CLINICAL ONCOLOGY ; MAY 20 2015, 33 15, 1p. Supplement: S- Subject
- Language
- English
- ISSN
- 15277755